Literature DB >> 29385372

Tolvaptan in Later-Stage Polycystic Kidney Disease.

Vicente E Torres1, Ron T Gansevoort2, Frank S Czerwiec3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29385372      PMCID： PMC6640143          DOI： 10.1056/NEJMc1716478

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Authors:  Maria V Irazabal; Vicente E Torres; Marie C Hogan; James Glockner; Bernard F King; Troy G Ofstie; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  Kidney Int       Date:  2011-05-04       Impact factor: 10.612

2.  Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Authors:  Wendy E Boertien; Esther Meijer; Paul E de Jong; Gert J ter Horst; Remco J Renken; Eric J van der Jagt; Peter Kappert; John Ouyang; Gerwin E Engels; Willem van Oeveren; Joachim Struck; Frank S Czerwiec; Dorothee Oberdhan; Holly B Krasa; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2015-01-15       Impact factor: 8.860

3.  Vasopressin stimulates Cl- transport in ascending thin limb of Henle's loop in hamster.

Authors:  N Takahashi; Y Kondo; O Ito; Y Igarashi; K Omata; K Abe
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

4.  Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.

Authors:  Toshinori Aoyagi; Yuichiro Izumi; Masami Hiroyama; Takanobu Matsuzaki; Yukiko Yasuoka; Atsushi Sanbe; Hiroki Miyazaki; Yoko Fujiwara; Yushi Nakayama; Yukimasa Kohda; Junji Yamauchi; Takeaki Inoue; Katsumasa Kawahara; Hideyuki Saito; Kimio Tomita; Hiroshi Nonoguchi; Akito Tanoue
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-30

5.  Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva
Journal:  N Engl J Med       Date:  2017-11-04       Impact factor: 91.245
  5 in total
  4 in total

Review 1.  Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era?

Authors:  Maria Yaseen; Waleed Hassan; Radwa Awad; Bilal Ashqar; Javier Neyra; Tagalie Heister; Omar Malik; Amr El-Husseini
Journal:  Kidney Dis (Basel)       Date:  2018-12-19

2.  Increased salt intake does not worsen the progression of renal cystic disease in high water-loaded PCK rats.

Authors:  Shizuko Nagao; Masanori Kugita; Kanako Kumamoto; Aya Yoshimura; Kazuhiro Nishii; Tamio Yamaguchi
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

3.  Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.

Authors:  Ming-Yang Chang; Shen-Hsing Hsu; Li-Yi Ma; Li-Feng Chou; Cheng-Chieh Hung; Ya-Chung Tian; Chih-Wei Yang
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

Review 4.  Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.

Authors:  Xia Zhou; Vicente E Torres
Journal:  Front Mol Biosci       Date:  2022-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.